---
title: "Jianmin Pharmaceutical Group Co., Ltd. (600976.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600976.SH.md"
symbol: "600976.SH"
name: "Jianmin Pharmaceutical Group Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-04-16T17:43:15.908Z"
locales:
  - [en](https://longbridge.com/en/quote/600976.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600976.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600976.SH.md)
---

# Jianmin Pharmaceutical Group Co., Ltd. (600976.SH)

## Company Overview

Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.whjm.com](https://www.whjm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:12.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 134 / 221 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.85% |  |
| Net Profit YoY | -0.65% |  |
| P/B Ratio | 1.96 |  |
| Dividend Ratio | 2.65% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5206494505.03 |  |
| Revenue | 3370996105.08 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.13% | B |
| Profit Margin | 10.68% | B |
| Gross Margin | 58.17% | B |
| Revenue YoY | -3.85% | D |
| Net Profit YoY | -0.65% | C |
| Total Assets YoY | 5.83% | C |
| Net Assets YoY | 9.24% | B |
| Cash Flow Margin | 76.29% | C |
| OCF YoY | -3.85% | D |
| Turnover | 0.77 | B |
| Gearing Ratio | 40.87% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jianmin Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.85%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.65%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.96",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.65%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5206494505.03",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3370996105.08",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.13%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "10.68%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "58.17%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-3.85%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.65%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.83%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.24%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "76.29%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-3.85%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.77",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.87%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.36 | 8/221 | 18.23 | 16.74 | 15.98 |
| PB | 1.94 | 71/221 | 2.50 | 2.36 | 2.03 |
| PS (TTM) | 1.53 | 20/221 | 1.90 | 1.79 | 1.64 |
| Dividend Yield | 2.67% | 32/221 | 2.64% | 2.30% | 2.20% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | C | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | B | B | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2024-11-21T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.68 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600976.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600976.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600976.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600976.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**